Peregrine Pharmaceuticals Inc (PPHM.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2017||Principal Executive Officer|
|48||2012||Chief Financial Officer|
|52||2012||Vice President, General Counsel, Corporate Secretary|
|50||2005||Vice President - Intellectual Property|
|43||2009||Vice President - Clinical & Regulatory Affairs|
- BRIEF-Peregrine Pharma reports Q2 shr loss $0.31
- BRIEF-Peregrine Pharma, Ronin Trading And SW Investment Management Announce Settlement Agreement
- BRIEF-Ronin Trading and SW Investment Management announce additional nominations to board of Peregrine pharmaceuticals
- BRIEF-Peregrine Pharmaceuticals appoints Mark Bamforth to board of Avid Bioservices and co
- BRIEF-Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board